IP Library Granted Patent US 8,242,079
Granted Patent B2
US 8,242,079 · App. 12/964,327 · Granted Aug 14, 2012

Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases

Assignee: Agennix Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,242,079
App. No.
12/964,327
Granted
Aug 14, 2012
Kind
B2
Abstract

The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.

Claims (12)

1. A method of treating non small cell lung and renal cancer in a mammalian subject in need thereof comprising administering chemotherapy, biotherapy, immunotherapy, surgery, radiotherapy, or a combination thereof to the subject in combination with orally administering to the subject a therapeutically effective amount of full-length mature human lactoferrin composition.

2. The method of claim 1 , wherein the lactoferrin composition is administered in combination with chemotherapy, radiotherapy, or both.

3. The method of claim 1 , wherein the chemotherapy comprises paclitaxel, docetaxel, doxorubicin, daunorubicin, adriamycin, mitomycin, actinomycin D, bleomycin, plicomycin, vincristine, vinblastine, cisplatin, etoposide, Tumor Necrosis Factor, carmustine, melphalan, cyclophosphamide, chlorambucil, busulfan, docetaxel, lomustine, carboplatin, procarbazine, mechlorethamine, irinotecan, topotecan, ifosfamide, nitrosurea, tamoxifen, raloxifene, toremifene, idoxifene, droloxifene, TAT-59, zindoxifene, trioxifene, ICI 182,780, EM-800, gemcitabinen, navelbine, transplatinum, 5-Fluorouracil, methotrexate, temazolomide, mylotarg, dolastatin-10, or bryostatin.

4. The method of claim 1 , wherein the chemotherapy comprises a platinum-based chemotherapy.

5. The method of claim 4 , wherein the platinum-based chemotherapy comprises cisplatin or carboplatin.

6. The method of claim 1 , wherein the chemotherapy comprises a taxane-based chemotherapy.

7. The method of claim 6 , wherein the taxane-based chemotherapy comprises docetaxel.

8. The method of claim 1 , wherein the chemotherapy comprises paclitaxel.

9. The method of claim 1 , wherein the lactoferrin composition is administered in combination with radiotherapy.

10. The method of claim 1 , wherein the lactoferrin composition is administered in combination with biotherapy.

11. The method of claim 1 , wherein the lactoferrin composition is administered in combination with immunotherapy.

12. The method of claim 1 , wherein the lactoferrin composition is administered in combination with surgery.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2011
From: VARADHACHARY, ATUL; BARSKY, RICK; PERICLE, FEDERICA; PETRAK, KAREL; WANG, YENYUN
To: AGENNIX INCORPORATED
Reel/Frame 025580/0429 →
Continuity (5)
Continuation 10434769 · May 9, 2003
Provisional Application 60379442 · May 10, 2002
Provisional Application 60379441 · May 10, 2002
Provisional Application 60379474 · May 10, 2002
Related Publication 20110076295A1 · Mar 31, 2011